Skip to main content
. 2022 Dec 12;128(6):940–945. doi: 10.1038/s41416-022-02096-8

Fig. 3. PPARγ alterations in PC (CBioPortal).

Fig. 3

PPARγ alterations visualised using CBioPortal [42, 43]. Prostate adenocarcinoma TCGA (51) was used as the primary prostate cancer cohort [40]. Metastatic prostate adenocarcinoma (SU2C/PCF) was used as the metastatic prostate cancer cohort [41]. For mRNA dysregulation, a z-score of >1.2 was used as a threshold relative to all samples.